Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis

Oncogene

Volumn 29, Issue 6, 2010, Pages 898-908

  Peuhu, E ^a,b   Rivero Muller A ^a   Stykki, H ^a,b   Torvaldson, E ^a,b   Holmbom, T ^b   Eklund, P ^b   Unkila, M ^c   Sjoholm R ^b   Eriksson, J E ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c Hormos Medical Ltd   (Finland)

Author keywords

Apoptosis; Lignans; Matairesinol; TRAIL

Indexed keywords

LIGNAN; MATAIRESINOL; PROTEIN BID; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL LINE, TUMOR; CELL POLARITY; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGNANS; MALE; MITOCHONDRIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 76849094300     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.386     Document Type: Article

References (41)

1. Adlercreutz H. (2007). Lignans and human health. Crit Rev Clin Lab Sci 44: 483-525.
2. Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T et al. (1993). Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 44: 147-153.
3. Aslan JE, You H, Williamson DM, Endig J, Youker RT, Thomas L et al. (2009). Akt and 14-3-3 control a PACS-2 homeostatic switch that integrates membrane traffic with TRAIL-induced apoptosis. Mol Cell 34: 497-509.
4. Axelson M, Sjovall J, Gustafsson BE, Setchell KD. (1982). Origin of lignans in mammals and identification of a precursor from plants. Nature 298: 659-660.
5. Bucur O, Ray S, Bucur MC, Almasan A. (2006). APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci 11: 1549-1568.
6. Bylund A, Saarinen N, Zhang JX, Bergh A, Widmark A, Johansson A et al. (2005). Anticancer effects of a plant lignan 7-hydroxymatair-esinol on a prostate cancer model in vivo. Exp Biol Med (Maywood) 230: 217-223. (Pubitemid 40293695)
7. Chen LH, Fang J, Li H, Demark-Wahnefried W, Lin X. (2007). Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway. MolCancerTher 6: 2581-2590.
8. Chen LH, Fang J, Sun Z, Li H, Wu Y, Demark-Wahnefried W et al. (2009). Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells. J Nutr 139: 653-659.
9. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C et al. (2001). Constitutively active akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083.
10. Danial NN, Korsmeyer SJ. (2004). Cell death: critical control points. Cell 116: 205-219.
11. Fulda S, Debatin KM. (2004). Signaling through death receptors in cancer therapy. Curr Opin Pharmacol 4: 327-332. (Pubitemid 38987057)
12. Hausott B, Greger H, Marian B. (2003). Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells. J Cancer Res Clin Oncol 129: 569-576.
13. Huang H, Zegarra-Moro OL, Benson D, Tindall DJ. (2004). Androgens repress bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene 23: 2161-2176.
14. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM et al. (2008). Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100: 1672-1694.
15. Jin Z, McDonald ER, Dicker DT, El-Deiry WS. (2004). Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279: 35829-35839.
16. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ. (2005). Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apopto-sis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem 280: 41047-41056.
17. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH et al. (1995). Cytotoxicity-dependent APO-1 (Fas/ CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14: 5579-5588.
18. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. (1999). Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 202: 91-100.
19. Koschny R, Walczak H, Ganten TM. (2007). The promise of TRAIL\-potential and risks of a novel anticancer therapy. J Mol Med 85: 923-935.
20. Li D, Yee JA, Thompson LU, Yan L. (1999). Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Lett 142: 91-96.
21. Lin X, Switzer BR, Demark-Wahnefried W. (2001). Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res 21: 3995-3999.
22. Mahalingam D, Szegezdi E, Keane M, Jong SD, Samali A. (2008). TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35: 280-288.
23. McCann MJ, Gill CI, Linton T, Berrar D, McGlynn H, Rowland IR. (2008). Enterolactone restricts the proliferation of the LNCaP human prostate cancer cell line in vitro. Mol Nutr Food Res 52: 567-580.
24. McCann MJ, Gill CI, McGlynn H, Rowland IR. (2005). Role of mammalian lignans in the prevention and treatment of prostate cancer. Nutr Cancer 52: 1-14.
25. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J et al. (1996). FLICE, a novel FADD-homologous ICE/ CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827.
26. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. (2001). Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774.
27. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. (1993). Lethal effect of the anti-fas antibody in mice. Nature 364: 806-809.
28. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. (1997). An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818.
29. Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL et al. (2008). The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther 7: 2212-2223.
30. Ray S, Bucur O, Almasan A. (2005). Sensitization of prostate carcinoma cells to Apo2 L/TRAIL by a bcl-2 family protein inhibitor. Apoptosis 10: 1411-1418.
31. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE et al. (2005). Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24: 6773-6784.
32. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI, Cohen MB. (2002). TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 1: 631-637.
33. Saarinen NM, Warri A, Dings RP, Airio M, Smeds AI, Makela S. (2008). Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer 123: 1196-1204.
34. Schaefer U, Voloshanenko O, Willen D, Walczak H. (2007). TRAIL: A multifunctional cytokine. Front Biosci 12: 3813-3824.
35. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al. (1997). Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821.
36. Sprick MR, Walczak H. (2004). The interplay between the bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 1644: 125-132.
37. Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C et al. (2001). Pro-survival function of Akt/protein kinase B in prostate cancer cells. relationship with TRAIL resistance. J Biol Chem 276: 38361-38369.
38. Thompson LU, Seidl MM, Rickard SE, Orcheson LJ, Fong HH. (1996). Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 26: 159-165.
39. Vincenz C, Dixit VM. (1997). Fas-associated death domain protein interleukin-1beta-converting enzyme 2 (FLICE2), an ICE/Ced-3 homologue, is proximally involved in CD95-and p55-mediated death signaling. J Biol Chem 272: 6578-6583.
40. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. (1998). Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58: 2720-2723.
41. Yokoyama T, Okano M, Noshita T, Funayama S, Ohtsuki K. (2003). Characterization of (\-)-matairesinol as a potent inhibitor of casein kinase I in vitro. Biol Pharm Bull 26: 371-374.